^
    13h
    GEN1046 Safety Trial in Patients With Malignant Solid Tumors (clinicaltrials.gov)
    P1/2, N=429, Active, not recruiting, Genmab | Trial completion date: Feb 2026 --> Aug 2026
    Trial completion date • First-in-human
    |
    Keytruda (pembrolizumab) • docetaxel • acasunlimab (GEN1046)
    18h
    BIOMATCH: Matching Primary Tumor and Blood Gene Expression Analysis of HPV-negative Squamous Head and Neck Cancers (clinicaltrials.gov)
    P=N/A, N=300, Recruiting, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
    New trial
    21h
    GALENOS 1 in Head and Neck, Lung, and Rectal Cancer Patients (clinicaltrials.gov)
    P=N/A, N=110, Recruiting, Fondazione del Piemonte per l'Oncologia
    New trial
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8) • CCL22 (C-C Motif Chemokine Ligand 22) • IL13 (Interleukin 13) • IL15 (Interleukin 15) • IL4 (Interleukin 4) • IL5 (Interleukin 5)
    21h
    NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P1/2, N=29, Active, not recruiting, University of Colorado, Denver | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • NT219
    1d
    ASP-1929-381: Study of the combination of the drug ASP-1929 and light illumination with the device PIT690 laser system in addition with pembrolizumab versus Standard of Care in the treatment of locoregional recurrent squamous cell carcinoma of the head and neck with no distant metastases (2025-523017-28-00)
    P2/3, N=30, Not yet recruiting, Rakuten Medical Inc.
    New P2/3 trial
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • paclitaxel • docetaxel • 5-fluorouracil • Akalux (cetuximab sarotalocan)
    2d
    Integrative Network Toxicology Reveals Lipoprotein Lipase as a Key Mediator of Dibutyl Phthalate-Associated Head and Neck Squamous Cell Carcinoma. (PubMed, Food Chem Toxicol)
    Functionally, DBP promoted SCC9 proliferation and reduced LPL expression, and was associated with transcriptional changes in PI3K-AKT-mTOR-related genes, whereas LPL restoration mitigated these effects. These findings reveal a novel DBP-LPL axis in HNSC.
    Journal
    |
    LPL (Lipoprotein Lipase)
    3d
    Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P2, N=126, Completed, Beijing Biostar Pharmaceuticals Co., Ltd. | Recruiting --> Completed | Trial completion date: Dec 2024 --> May 2025 | Trial primary completion date: Mar 2024 --> May 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    utidelone IV (UTD1)
    4d
    Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan (clinicaltrials.gov)
    P1, N=694, Recruiting, AbbVie | N=512 --> 694 | Trial primary completion date: Jul 2026 --> Jul 2027
    Enrollment change • Trial primary completion date • Adverse events • First-in-human
    |
    PD-1 (Programmed cell death 1)
    |
    BRAF V600E • BRAF V600 • HER-2 mutation
    |
    Avastin (bevacizumab) • budigalimab (ABBV-181) • telisotuzumab adizutecan (ABBV-400)
    4d
    The Prognostic Value of SERPINE1 in Clinical Outcomes in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis. (PubMed, Technol Cancer Res Treat)
    In contrast, no clear associations were observed for PFS or DSS (P ≥ 0.05).ConclusionCurrent evidence suggests that increased SERPINE1 expression is associated with an unfavorable prognosis in HNSCC, particularly for OS and DFS. Larger prospective studies are needed to confirm these findings and to determine how SERPINE1 assessment might be incorporated into risk stratification and treatment planning for patients with HNSCC.
    Clinical • Clinical data • Retrospective data • Review • Journal
    |
    SERPINE1 (Serpin Family E Member 1)
    4d
    Case Report: A case of severe hypotension induced by nimotuzumab in a nasopharyngeal carcinoma patient. (PubMed, Front Immunol)
    After discontinuing the drug and giving continuous norepinephrine to increase BP, the patient's BP returned to stable. This case suggests that although nimotuzumab-related hypotension is mostly mild and reversible, BP monitoring should still be strengthened to maintain vigilance against severe hypotension and intervene promptly in clinical practice.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR expression • EGFR positive
    |
    TheraCIM (nimotuzumab)
    4d
    CCL26-Mediated Modulation of Endothelial Secretome by Hypoxia-Induced Tumor-Derived Exosomes Enhances Metastatic Progression in Head and Neck Cancer. (PubMed, Head Neck)
    hiTDExs reprogram endothelial secretomes by elevating CCL26, promoting tumor-supportive phenotypes and driving metastatic progression in HNSCC.
    Journal
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit) • CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1) • CCR3 (C-C Motif Chemokine Receptor 3)
    4d
    Ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial. (PubMed, Lancet Oncol)
    The maximum tolerated dose was not reached with ifinatamab deruxtecan; however, one death due to treatment-related interstitial lung disease highlights the importance of prompt evaluation and careful management of patients who develop interstitial lung disease. Promising antitumour activity was observed across various solid tumours. These findings support further evaluation of ifinatamab deruxtecan in randomised controlled trials.
    P1/2 data • Journal • Pan tumor • First-in-human
    |
    CD276 (CD276 Molecule)
    |
    ifinatamab deruxtecan (DS-7300)